Which listed company is Fosun Kate?

Answer: Fosun Kate Biotechnology Co., Ltd. was established in April of 17. The legal representative is Richard Wang Liqun.

The business scope of the company includes: technology development, technology transfer, technical consultation, technical service and technology achievement transfer in the fields of biotechnology and medical science and technology (except diagnosis and treatment, psychological consultation, development and application of human stem cells and gene diagnosis and treatment technology); Pharmaceutical production; Chemical products (except dangerous chemicals, monitoring chemicals, fireworks and firecrackers, civil explosives and precursor chemicals), import and export of instruments and equipment, wholesale and commission agency (except auction), investment consulting (except finance and securities), etc.

On March 30, 2020, Fosun Pharma, a holding subsidiary, and KP EU C.V (hereinafter referred to as "Kite 5 Medicine") signed the Amendment to the Sino-foreign Cooperative Operation Contract (III), and Fosun Pharma and Kite Pharma intend to increase their capital according to their respective shareholding ratios in Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as "Fosun Kate"). Among them, Fosun Pharma intends to subscribe for the newly-increased registered capital of Fosun Kate in cash equivalent to US$ 5 million (the exchange rate is converted according to the central parity between the US dollar and RMB announced by the People's Bank of China on the actual investment date). After these capital increases are completed, the company still holds 50% equity of Fosun Kate.

On July 6, 2020, Fosun Pharma, a holding subsidiary, and Kite Pharma signed the Amendment to the Sino-foreign Joint Venture Contract (IV), and Fosun Pharma and Kite Pharma intend to increase the capital of Fosun Kate according to their respective shareholding ratios. Among them, Fosun Pharma intends to subscribe for the newly-increased registered capital of Fosun Kate in cash equivalent to USD 65,438+RMB 0,000,000 (the exchange rate is converted according to the central parity between USD and RMB announced by the People's Bank of China on the actual investment date). After these capital increases are completed, the company still holds 50% equity of Fuxing Kate.

On September 17, 2020, Fosun Pharma and Kite Pharma, the holding subsidiaries, signed the Amendment to the Sino-foreign Cooperative Operation Contract (V), and Fosun Pharma and Kite Pharma intend to increase the capital of Fosun Kate according to their respective shareholding ratios. Among them, Fosun Pharma intends to subscribe for the newly-increased registered capital of Fosun Kate in RMB equivalent to USD 6 million in cash (the exchange rate is converted according to the central parity between USD and RMB announced by the People's Bank of China on the actual investment date). After the capital increase is completed, the company still holds 50% equity of Fosun Kate.

Fosun Kate is a joint venture between Fosun Pharma and Kite Pharmaceutical (a subsidiary of Gilead Science), which is committed to the research and development of tumor immune cell therapy products and the standardization of industrialization. In March 2020, the company's first CAR-T cell therapy product, Akerlinsai Injection (FKC876), was included in the priority review by the Drug Evaluation Center of the State Pharmaceutical Products Administration, becoming the first CAR-T cell therapy product approved for listing in China (currently under review, it has not been approved for listing in China). At the same time, the CAR-T industrial production base with an area of nearly 1 10,000 square meters has been built and put into use in Zhangjiang Innovative Pharmaceutical Industry Base, preparing for the product approval and listing. In addition, the 2000-square-meter cell therapy R&D center and innovative talent team, through independent innovation and international cooperation, focus on CAR-T/TCR-T early research and development and clinical evidence-based projects to create a sustainable innovative R&D pipeline.